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Cell penetrating peptides have been regarded as promising vectors to deliver hydrophilic
molecules inside cells. Although they are great tools for research and have high potential
as drug delivery systems, their application as drugs is impaired by their low stability in
serum. Cyclotides, cyclic disulfide-rich peptides from plants, are ultra-stable molecules that
have inspired applications in drug design as they can be used as scaffolds to stabilize linear
bioactive sequences. Recently, they have also been shown to possess cell-penetrating
properties. The combination of their remarkable stability and cell-penetrating properties
opens new avenues for the application of peptides to bind to and inhibit intracellular
proteins. Nevertheless, for a broader application of these molecules as vectors is of
utmost importance to improve their cellular internalization efficiency. In this study we
successfully modified MCoTI-II, one of the most widely studied cyclotide scaffolds in
drug design, and improved its internalization properties. The internalization of the newly
designed MCoTI-II is as efficient as the gold standard cell-penetrating peptide (CPP) TAT
and maintains all the required features as a template to graft desired bioactivities.
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INTRODUCTION
Despite their high selectivity, potency and low toxicity, peptides
have in the past been discounted as good therapeutics due to
their poor stability and low delivery efficiency. However, recent
advances that improve their stability have stimulated interest in
pursuing peptides as alternative therapeutics. In particular, the
discovery of stable disulfide-rich peptides with high potency,
specificity and tolerance to sequence modification have provided
strong support for the use of peptides as therapeutic templates
(Craik et al., 2013). Examples include disulfide-rich toxins iso-
lated from the venoms of cone snails, which have exquisite
selectivity for membrane receptors (Schroeder and Craik, 2012).
The peptide field also received renewed interest upon the dis-
covery of positively-charged sequences, named cell-penetrating
peptides (CPPs), able to carry and translocate large proteins or
other hydrophilic molecules, into cells (Henriques et al., 2006).
Although a proven research tool, CPPs still have limitations for
therapeutic protein delivery due to the low enzymatic stability of
the CPP protein conjugates, a drawback in both oral and injection
delivery.
Cyclotides are a fascinating class of cyclic disulfide-rich pep-
tides that have inspired applications of peptides in drug design.
Isolated from plants, cyclotides are characterized by a cyclic
peptide backbone together with three-disulfide bonds arranged
in a knot, referred to as a cyclic cystine knot (CCK) motif
(Figure 1A) (Craik et al., 1999). This structural motif con-
fers cyclotides with remarkable stability, which combined with
their amenability to modification, has stimulated their use as a
drug scaffold (Henriques and Craik, 2010; Poth et al., 2013).
Specifically, the backbone portions between cysteine residues,
referred to as loops, can be modified to incorporate foreign
bioactive peptide sequences. The grafting of these bioactive
regions confers cyclotides with specific activities without dis-
turbing the overall fold and can be used to inhibit therapeutic
targets.
Cyclotides have been successfully modified to incorporate a
wide range of desired activities (Poth et al., 2013). Examples
include reengineered cyclotides with angiogenic activity and
potential wound healing properties (Chan et al., 2011), peptides
that target melanocortin receptors with the potential to treat obe-
sity (Eliasen et al., 2012), molecules with immuno-regulatory
activity and molecules with capacity to target multiple sclero-
sis (Wang et al., 2014), as well as peptide-based inhibitors of
matriptase, a target for breast cancer (Quimbar et al., 2013). All
these modified cyclotides were designed to target extracellular or
membrane-bound receptors.
Interestingly, some cyclotides have been found to possess cell-
penetrating properties (Greenwood et al., 2007; Cascales et al.,
2011; Contreras et al., 2011). The identification of such a prop-
erty suggests that cyclotides can be used, not only as a template to
stabilize bioactive peptide sequences, but also as a vector to intro-
duce the bioactive sequences inside cells. This potential suggests
that reengineered cyclotides could be used to inhibit intracellu-
lar protein/protein interactions and further extend their potential
application as therapeutics. This promising potential has been
recently realized with a pioneering work by Camarero’s group,
in which an 18-amino acid sequence was grafted into loop 6
of Momordica cochinchinensis trypsin inhibitor I (MCoTI-I) and
shown to inhibit the intracellular interaction of p53 with the
oncoprotein Hdm2 in vitro and in a mouse model (Ji et al., 2013).
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FIGURE 1 | Structure of MCoTI-II. (A) Three-dimensional structure
(left; PDB ID: lib9) and sequence of native MCoTI-II (right) showing
the cyclic backbone and the three disulfide bonds (shown in
yellow) arranged in a knot, the signature features of cyclotides. The
position of the first residue (G1) is shown in the three-dimensional
structure with a dashed line. The backbone segments between Cys
are named loops 1–6 and the Cys residues are numbered with
I–VI. (B) Surface representation of MCoTI-II shown in two views.
Positively-charged (blue) and negatively-charged (red) residues are
labeled.
So far, MCoTI-I and closely related MCoTI-II are the
cyclotides that have been extensively studied for their internal-
ization properties, and also two of the preferred scaffolds in drug
design (Poth et al., 2013). Nevertheless, their internalization effi-
ciency, when compared with typical linear CPPs, is rather low
(D’Souza et al., 2014). Our hypothesis is that, for an efficient and
broad application of cyclotides as frameworks to deliver bioac-
tive sequences into cells, it is of major importance to improve the
internalization efficiency of MCoTI-II. Therefore, in the current
study we have modified MCoTI-II to improve the intracellular
uptake, without compromising the low toxicity and ability to be a
good template for drug design.
MATERIALS AND METHODS
PEPTIDE SYNTHESIS AND LABELING
MCoTI-II and its analogs were synthesized using manual
solid phase peptide synthesis (SPPS) based on Boc-chemistry
as described previously (Chan et al., 2011), but using 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hex-
afluorophosphate (HCTU) as the coupling reagent. Peptides were
cleaved from the resin using hydrogen fluoride with the scav-
enger p-cresol at 0◦C for 1 h. Crude peptides were purified using
Phenomenex C18 columns on reversed-phase high-performance
liquid chromatography (RP-HPLC). Cyclization and oxidation of
the peptides was achieved by incubating the linear reduced pep-
tides in 0.1M ammonium bicarbonate (pH 8.5) for 24 h and
the resulting peptides were purified using RP-HPLC with 1%
gradient of 0–80% of solvent B (acetonitrile 90% (v/v) with
0.045% (v/v) trifluoroacetic acid (TFA) in H2O) in solvent A
(0.05% (v/v) TFA in H2O) to>95% purity. The mass of peptides
was confirmed using electrospray ionization mass spectrome-
try (ESI-MS) and the purity of peptides was verified using an
ultra high performance liquid chromatography system (UHPLC,
Shimadzu) with 4%/min gradient of 5–35% solvent B on an
analytical C18 column (RRHD 2.1 × 50mm, 1.8μm, Agilent).
Linear peptides TAT (NH2-YGRKKRRQRRRPPQG-COOH) and
modified CTP512 with one of the Arg residues replaced with
a Lys residue for labeling purpose (NH2-YGRKARRRRRR-
COOH) were synthesized using SPPS based on Fmoc-chemistry
on an automated peptide synthesizer (Symphony®, Protein
Technologies) and cleaved as described previously (Cheneval
et al., 2014).
Peptides were labeled with Alexa fluor® 488 sulfodichlorophe-
nol ester (Life Technologies) through the side-chain amine of Lys
residue as described before (Torcato et al., 2013a). The reten-
tion time and the purity of labeled peptides were determined
using UHPLC. The mass of peptides was confirmed using ESI-
MS. Quantification of singly-labeled peptides was performed
using Lambert-Beer law with the absorbance of the dye at
495 nm (ε495 = 71, 000M−1cm−1) (D’Souza et al., 2014). Non-
labeled peptides were quantified following absorbance at 280 nm
(ε280 = 1865M−1cm−1 for MCoTI-II and MCo-RM1, and 3355
M−1cm−1 for MCo-CTP).
CELL CULTURE
Adherent human cervix epitheloid carcinoma (HeLa) cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM; sup-
plemented with 1% (v/v) penicillin/streptomycin and 10% (v/v)
of fetal bovine serum) at 37◦C in humidified atmosphere con-
taining 5% CO2. Cells were split every 2 days or after reaching
confluence with ¼ dilution. HeLa cells were seeded in a 24-well
plate with 1 × 105 cells per well the day before the internalization
assay.
INTERNALIZATION ASSAY
Internalization of fluorescently-labeled peptides into HeLa cells
was followed by flow cytometry as described previously (Torcato
et al., 2013a; D’Souza et al., 2014). Briefly, Alexa fluor® 488
labeled TAT, CTP512, MCoTI-II, MCo-RM1 and MCo-CTP
at concentrations varying from 0.25 to 8μM were incubated
with HeLa cells for 1 h at 37◦C in medium without serum.
Non-internalized peptides were washed with cold phosphate
buffer solution (PBS) and cells were harvested from the plate
by trypsinization, spun at 1500 rpm at 4◦C and resuspended
in cold PBS. Cell mean fluorescence emission was measured
by flow cytometry (BD FACSCanto™ II) by analyzing 10,000
cells per sample with excitation at 488 nm and emission at
530/30 nm, before and after the addition of trypan blue (TB;
160μg/mL). Experiments were repeated on three independent
days.
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CYTOTOXICITY ASSAY
Toxicity to HeLa cells induced by non-labeled peptides was exam-
ined with 2-fold dilutions starting from 64μM and quantified
using a resazurin assay as detailed before (Torcato et al., 2013b).
Experiments were done in duplicate.
SERUM STABILITY
The stability of peptides in human serum was examined using
a protocol reported previously (Chan et al., 2011). Briefly, stock
solutions of peptides (300μM) were diluted 10 times with pre-
warmed 100% human serum isolated from male AB plasma
(Sigma-Aldrich) and incubated at 37◦C for 0, 1, 2, 3, 5, 8, 12 and
24 h. Controls with peptides in PBS were included. The reaction
was stopped by denaturing the serum proteins with urea at a final
concentration of 3M at 4◦C for 10min, followed by precipitation
of serum proteins with trichloroacetic acid at a final concen-
tration of 7% (v/v) (4◦C, 10min) and centrifugation (17,000 g,
10min). The supernatant of each sample was recovered and run
on an analytical column using a linear gradient of 5–30% sol-
vent B (acetonitrile 90% (v/v) with 0.045% (v/v) TFA in H2O)
in solvent A (0.05% (v/v) TFA in H2O) over 25min at a flow rate
of 0.3mL/min with monitoring at 215 nm. The elution profile of
each peptide was identified by the PBS sample from 0 time point.
The percentage of peptide remaining in serum-treated samples
was determined by comparing the height of the peptide peak
obtained at each time point with that of the peptide peak obtained
at 0 time point. Each experiment was done in triplicate.
1H NMR SPECTROSCOPIC CHARACTERIZATION
Lyophilized peptides (purity> 95%) were dissolved in 10% (v/v)
D2O to a final concentration of 1mM.One- and two-dimensional
TOCSY (total correlation spectroscopy) and NOESY (nuclear
overhauser effect spectroscopy) spectra of MCoTI-II, MCo-RM1
and MCo-CTP were acquired using an Avance-600 MHz spec-
trometer (Bruker) at 25◦C. The mixing time was 80ms and 200–
300ms for TOCSY and NOESY, respectively. Spectra were inter-
nally referenced to 2,2-dimethyl-2-silapentane-5-sulfonic acid
(DSS) at 0.00 ppm and analyzed using SPARKY (version 3.114).
The backbone secondary chemical shifts of peptides were cal-
culated for each residue using the random coil chemical shifts
(Wishart et al., 1995).
RESULTS
REENGINEERING THE CYCLOTIDE FRAMEWORK
Previous studies onMCoTI-II and its analogs have shown that the
overall positive charge and the distribution of the basic residues
on the surface of the molecule (Figure 1B) are important for
its cellular internalization (Cascales et al., 2011; D’Souza et al.,
2014). In general it has been shown that Arg residues, compared
to Lys residues, improve translocation of CPPs (Fuchs and Raines,
2006; Sundlass and Raines, 2011). The guanidinium group of
Arg is able to form additional hydrogen bonds, compared to the
ammonium group of Lys, and therefore more readily binds to car-
boxyl, phosphoryl and sulfuryl groups at the cell surface. Thus, we
first designed an analog, MCo-RM1 (Table 1), in which all the Lys
residues in the positive patch (see Figure 1B) were replaced with
Arg residues. In this analog, Arg 24 in loop 5 was also replaced
with a Lys. The purpose of this modification was to introduce a
Lys side chain for the fluorescent labeling required for the inter-
nalization studies and to have the fluorescent probe away from the
positively-charged patch.
MCo-RM2 andMCo-RM3 were designed to increase the over-
all charge. All the acidic residues in MCo-RM2 were replaced
with basic residues (Asp to Arg in loop 2 and Asp to Lys in
loop 6), whereas the loop 2 of MCo-RM3 was replaced with
a longer sequence containing extra Arg residues and two Ala
residues intermediating the Arg residues to potentially help in the
peptide assembly and folding. Both MCo-RM2 and MCo-RM3
have the Asp residue in loop 6 replaced with a Lys. This mod-
ification was included to further increase the overall charge of
these peptides and to place the fluorescent label away from the
positively-charged patch.
MCo-CTP includes a portion of a previously identified CPP
sequence, CTP512 (Kim et al., 2006). This sequence, based on
TAT, was shown to be better internalized and to have higher
distribution within the cytoplasm than TAT. Because TAT is a
nuclear localization sequence, it is likely to direct fused pro-
teins toward the nucleus; therefore, CTP512 was designed to
retain the ability to translocate through the cell membrane but to
remain in the cytoplasm after internalization. MCo-CTP incor-
porates a sequence derived from CTP512 into loop 1 of the
MCoTI-II scaffold and a Lys for labeling into loop 5 (Lys 26, see
Table 1).
SYNTHESIS, OVERALL FOLD AND TRIDIMENSIONAL STRUCTURE OF
REENGINEERED PEPTIDES
Novel designed MCoTI-II peptides were assembled using SPPS
based on Boc-chemistry and cyclized and oxidized with ammo-
nium bicarbonate buffer at pH 8.5. Purification with acetoni-
trile gradient and a first assessment of folding were conducted
using RP-HPLC and ESI-MS; chromatograms of both MCo-
RM1 and MCo-CTP showed typical profiles of cyclized and
Table 1 | Sequences of MCoTI-II and its analogs used in this study.
Peptide Loop 6 I Loop 1 II Loop 2 III Loop 3 IV 4 V Loop 5 VI Loop 6 Chargea
MCoTI-II GGV C PKILKK-- C RRDSD---- C PGA C I C RGNGY C GSGSD +3
MCo-RM1 GGV C PRILRR-- C RRDSD---- C PGA C I C KGNGY C GSGSD +3
MCo-RM2 GGV C PRILRR-- C RRRSR---- C PGA C I C RGNGY C GSGSK +9
MCo-RM3 GGV C PRILRR-- C RRARRRARR C PGA C I C RGNGY C GSGSK +12
MCo-CTP GGV C YGRRARRR C RRDSD---- C PGA C I C KGNGY C GSGSD +5
aOverall peptide charge at pH 7.4.
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oxidized cyclotides, whereas the chromatograms obtained for
MCo-RM2 and MCo-RM3 showed multiple peaks correspond-
ing to misfolded isomers. Folding trials with various condi-
tions were conducted, but no improvement in the folding was
achieved. Thus, additional studies with MCo-RM2 and MCo-
RM3 could not be performed. Details on the characterization
of the peptides (i.e., UHPLC retention time, purity percentage
and the observed m/z values) are included in Supplementary
Table 1.
After purification of MCo-RM1 and MCo-CTP, the overall
fold of the peptides was evaluated by 1H NMR spectroscopy.
The secondary α-proton chemical shifts of MCo-RM1 and MCo-
CTP in the gray-shaded regions of Figure 2A are comparable
to those of native MCoTI-II. Differences in chemical shifts are
only evident in loop 1, where residues were substituted, and the
flanking regions. These results suggest that the overall structure
of the designed peptides is similar to that of the native scaf-
fold. The three-dimensional (3D) structure of the engineered
MCo-CTP was predicted using Modeler 9v2 (Sali and Blundell,
1993) based on the known 3D structure of MCoTI-II (PDB:
1IB9) (Felizmenio-Quimio et al., 2001), and its surface struc-
ture was generated using PyMOL Molecular Graphics System
(Version 1.5.0.4 Schrödinger, LLC; www.pymol.org). Figure 2B
shows that the newly designed molecule MCo-CTP contains a
positively-charged patch at the surface.
INTERNALIZATION INTO HeLa CELLS
The internalization efficiency of the various peptides was mea-
sured by comparing their uptake into HeLa cells. All the peptides
were conjugated with a single Alexa fluor® 488 molecule and had
a purity of >93%, as confirmed by ESI-MS and UHPLC (see
Supplementary Table 1). HeLa cells were treated with a range
of concentrations, varying from 0.25 to 8μM, of each labeled
peptide for 1 h at 37◦C and the percentage of fluorescent cells
and mean fluorescence emission intensity of Alexa fluor® 488
measured by flow cytometry as before (Torcato et al., 2013a)
(Figure 3).
Virtually all the cells became fluorescent upon treatment
with 8μM of the tested peptides (the percentage of fluorescent
cells was >97%, Figure 3A), confirming the ability of MCoTI-II
and its analogs to target HeLa cells. The percentage of fluo-
rescent cells did not change after the addition of trypan blue
(TB), an aqueous fluorescence quencher unable to enter viable
cells. This observation confirms that the internalization occurred
through a non-permeabilizing mechanism (Torcato et al., 2013a).
Furthermore, the mean fluorescence emission did not have a sig-
nificant drop after the addition of TB (Figure 3B and Table 2).
The fact that the fluorescent peptides were inaccessible to the
aqueous environment suggests that the peptides were not cell
surface-associated but internalized inside the cell. This is in agree-
ment with previous studies on MCoTI-II that showed it has only
a weak ability to bind to model lipid membranes (Cascales et al.,
2011; D’Souza et al., 2014).
The uptake efficiency of the tested peptides was ranked by
comparison of the mean fluorescence emission obtained after
the addition of TB, and followed the trend: MCoTI-II < MCo-
RM1 < MCo-CTP ∼ TAT < CTP512. MCo-RM1 has a 22%
improvement in internalization efficiency compared to its par-
ent peptide MCoTI-II, whereas MCo-CTP has a 2.4-fold increase
and has equivalent internalization efficiency to TAT (see Table 2
and Figure 3B). Although the observed internalization of MCo-
CTP was lower than that of CTP512, the grafting of a linear
CPP sequence intoMCoTI-II scaffold improves its internalization
efficiency.
TOXICITY AND STABILITY OF NOVEL PEPTIDES
None of the peptides showed cytotoxicity against HeLa cells at
concentrations up to 64μM, as assayed using a resazurin test
(data not shown). To evaluate whether the designed peptides
retained the stability of the native MCoTI-II scaffold, they were
FIGURE 2 | Structure of MCoTI-II analogs. (A) Secondary α-proton chemical
shifts of MCoTI-II, MCo-RM1, and MCo-CTP determined by two-dimensional
NMR spectroscopy. The observed secondary chemical shifts of MCoTI-II,
MCo-RM1 and MCo-CTP are plotted as dark gray, yellow and blue bars,
respectively. The peptide sequences are shown below the graph. Regions
with identical sequences are shaded in light gray. The six Cys residues are
highlighted with black boxes and labeled with Roman numerals I–VI. The
dotted lines indicate the shift changes at 0.1 and –0.1 ppm. (B) Surface
structure representation of MCo-CTP, shown in two views (flipped by 180◦),
as modulated based on MCoTI-II structure (PDB ID: lib9) using modeler and
PyMOL. Positively-charged and negatively-charged residues are shown in
blue and red, respectively.
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FIGURE 3 | Internalization of peptides into HeLa cells. Cells were
treated with 8μM of fluorescently-labeled peptides for 1 h at 37◦C and
the internalization was measured by fluorescence emission of Alexa
fluor® 488 using flow cytometry [excitation at 488 nm and detection at
530 nm (band pass 30 nm)]. The fluorescence emission was measured
before and after the addition of trypan blue (TB; 160μg/mL); 10,000
cells were analyzed per sample. (A) Dotplots showing the side scatter
(SSC) as function of the fluorescence emission intensity obtained after
addition of TB; both axes are in log scale. The gate of fluorescent cells
was drawn with the blank (without peptide) to exclude dark events. (B)
Mean fluorescence intensity obtained with peptide-treated cells before
and after addition of TB. The fluorescence signal was normalized to TAT
after addition of TB. Data are represented as mean ± SD of three
independent experiments (see values in Table 2); the statistical analysis
was performed by One-Way ANOVA by comparison with TAT (∗p < 0.05,
∗∗∗p < 0.001).
Table 2 | Fluorescence signal of HeLa cells after treatment with
labeled peptidesa.
Peptide Before trypan blue After trypan blue
TAT 1.08 ± 0.07 1.00 ± 0.17
CTP512 1.54 ± 0.40 1.46 ± 0.36
MCoTI-II 0.33 ± 0.04 0.32 ± 0.03
MCo-RM1 0.41 ± 0.02 0.39 ± 0.03
MCo-CTP 0.85 ± 0.14 0.78 ± 0.12
aCells were treated with 8μM of Alexa fluor® 488 -labeled peptides for 1 h
at 37◦ C and the mean fluorescence emission intensity of 10,000 cells was
measured using flow cytometry. The mean fluorescence emission signal was
normalized for the signal obtained with TAT after treatment with trypan blue.
incubated with human serum and the portion of peptide remain-
ing was quantified by analytical-HPLC. Figure 4 shows that the
linear CTP512 was fully degraded by proteases in serum within
1 h, whereas MCoTI-II and all the analogs were stable for several
hours. Unlike MCo-RM1, MCo-CTP is less stable than its parent
peptide MCoTI-II; nevertheless, more than 60% of the peptide
remained intact after 12 h incubation in serum. These results con-
firm that the CCK structure prevents enzymatic degradation of
grafted sequences, even those containing a large number of basic
residues.
DISCUSSION
Arising from the success of MCoTI-II as a novel scaffold for drug
design (Poth et al., 2013), in the present study we were interested
in improving the uptake of this peptide for its more efficient use
as a drug template and delivery system to inhibit intracellular tar-
gets. Loop 6 of this peptide is normally preferred to graft desired
bioactive sequences as it is the longest and most flexible loop in
MCoTI-II and therefore the most likely to keep the conformation
FIGURE 4 | Serum-stability of tested peptides. Percentage of peptide
remaining upon incubation with human serum. The portion of serum-treated
peptide remaining was determined by calculating the height of the
respective elution peak in analytical-HPLC and comparing it with control
without incubation. Data points are means ± SD of three experiments.
of foreign sequences. With this in mind we tried to improve the
cell-penetrating properties of MCoTI-II without modification of
loop 6.
The rationale behind the designed peptides was to improve
the positively-charged patch at the surface of MCoTI-II, and
this was proved to be a successful strategy, as the uptake effi-
ciency increased by ∼20% for MCo-RM1 and to ∼240% for
MCo-CTP. The analog MCo-RM2, in which all the negatively-
charged residues were replaced with basic residues, did not fold,
suggesting that the negatively-charged residues in loop 2 are
important to keep the overall structure of the scaffold and prob-
ably help form the correct disulfide connectivity. This shows
that, although positive charges are required for the internaliza-
tion of MCoTI-II, a balance between positive and negatively-
charged residues is required to efficiently fold the MCoTI-II
structure.
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Both MCo-RM1 and MCo-CTP kept the overall structure of
MCoTI-II and were stable in human serum. Grafting the CTP512
into the MCoTI-II scaffold strikingly increases the stability of
this linear CPP, as shown with MCo-CTP. This clearly shows that
using a cyclotide scaffold as a strategy to translocate bioactive
molecules into cells is a desirable alternative to linear CPPs. It
is worth mentioning that for the purpose of labeling, the MCo-
CTP has its Arg in loop 5 replaced with a Lys, but for potential
therapeutic applications, as labeling will not be required, the orig-
inal Arg could be kept, as this might improve its uptake efficiency.
Without the label the overall charge of MCo-CTP is higher, so the
overall uptake is expected to be higher than that of the labeled
peptide shown in this study.
Previous mechanistic studies of MCoTI-I and MCoTI-II sug-
gested that these peptides enter cells via endocytic pathways
and lack membrane-binding properties (Cascales et al., 2011;
Contreras et al., 2011; D’Souza et al., 2014). Although mechanis-
tic studies were not within the scope of the current study, based
on the internalization results we postulate that the designed pep-
tides do not bind strongly to membranes and probably enter cells
following the same mechanism as the native MCoTI-II.
Intracellular protein-protein interactions are traditionally
considered “undruggable” as protein-protein interfaces are too
large to be inhibited by small-molecule approaches and not
accessible to antibodies, unable to cross the cell membrane.
Nevertheless, new developments in the peptide field have shown
that inhibition of intracellular proteins is possible and hidden
drug targets are now starting to be explored (Hoe et al., 2014). In
the current study we have shown that cyclotides can be modified
to improve their internalization, while maintaining loop 6 (pre-
ferred for grafting) intact and high resistance to protease degra-
dation. The reengineered MCoTI-II (Figure 5) with improved
cellular uptake can be used as a novel cyclotide scaffold to sta-
bilize a bioactive linear peptide and deliver it efficiently inside the
cells to inhibit intracellular protein-protein interactions.
FIGURE 5 | Diagram of ameliorated cyclotide scaffold. The modified
cyclotide retains the overall fold, stability and loop 6 to graft bioactive linear
sequences (represented in red) but has improved cellular uptake due to
incorporation of a cell-penetrating peptide with extra positive charges
(represented in blue).
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